VivoSeq
Other

Efficacy and Safety

0

Pipeline Programs

368

Active Trials

348

Companies Involved

Efficacy and Safety is an early-stage landscape with 0 programs across 348 companies. The most active players are Novartis, AstraZeneca, Pfizer.

Pipeline Metrics

Competitive Density

78/100

Pipeline Velocity

89/100

Mech. Concentration

N/A

Completion Rate

87/100

Attrition Rate

9/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

2,364

clinical trials

Completed1,449 · 61%
Unknown status322 · 14%
Recruiting181 · 8%
Terminated155 · 7%
Not yet recruiting106 · 4%
Active, not recruiting75 · 3%
Other76 · 3%

Trial Activity

2364 trials

Efficacy and Safety of EsoDuo®
Recruiting·Chong Kun Dang Pharmaceutical logoChong Kun Dang Pharmaceutical·Phase 4·NCT06430047·180 enrolled
The Efficacy and Safety of HCQ Plus TPO-RA in ANA Positive ITP
Recruiting··N/A·NCT06479291·126 enrolled
Page 1 of 158

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)